
1. plos negl trop dis. 2016 oct 6;10(10):e0005009. doi:
10.1371/journal.pntd.0005009. ecollection 2016 oct.

plasmodium vivax vir proteins targets naturally-acquired antibody t
cell immune responses malaria pregnant women.

requena p(1)(2), rui e(1), padilla n(3), martínez-espinosa fe(4)(5), castellanos 
me(3), bôtto-menezes c(4)(6), malheiro a(7), arévalo-herrera m(8), kochar s(9),
kochar sk(9), kochar dk(9), umbers aj(10), ome-kaius m(11), wangnapi r(11), hans 
d(12), menegon m(13), mateo f(1), sanz s(1), desai m(14), mayor a(1), chitnis
cc(12), bardají a(1), mueller i(1)(15), rogerson s(10), severini c(13),
fernández-becerra c(1), menéndez c(1), del portillo h(1)(16), dobaño c(1).

author information: 
(1)isglobal, barcelona ctr. int. health res. (cresib), hospital clínic -
universitat de barcelona, barcelona, spain.
(2)department parasitology, liverpool school tropical medicine, liverpool, 
united kingdom.
(3)centro de estudios en salud, universidad del valle de guatemala, guatemala
city, guatemala.
(4)fundação de medicina tropical dr. heitor vieira dourado, manaus, amazonas,
brazil.
(5)instituto leônidas e maria deane (ilmd/fiocruz amazonia), brazil.
(6)universidade estado amazonas, manaus, amazonas, brazil.
(7)instituto de ciências biológicas. universidade federal amazonas, manaus,
brazil.
(8)caucaseco scientific research center/universidad del valle, cali, colombia.
(9)department medicine, medical college, bikaner, rajasthan, india.
(10)department medicine, university melbourne, melbourne, australia.
(11)papua new guinea institute medical research, madang, papua new guinea.
(12)international center genetic engineering biotechnology, delhi, india.
(13)department infectious, parasitic immunomediated diseases, istituto
superiore di sanità, rome, italy.
(14)centers disease control prevention, division parasitic diseases
and malaria, malaria branch, atlanta, georgia, united states america.
(15)walter eliza hall institute, parkville, australia.
(16)icrea, barcelona, spain.

p. vivax infection pregnancy associated poor outcomes such
as anemia, low birth weight congenital malaria, thus representing an
important global health problem. however, vaccine currently available for
its prevention. vir genes first putative virulent factors associated
with p. vivax infections, yet studies examined potential role
as targets immunity. investigated immunogenic properties five vir
proteins two long synthetic peptides containing conserved vir sequences
(pvlp1 pvlp2) context pregvax cohort study including women from
five malaria endemic countries: brazil, colombia, guatemala, india papua new 
guinea (png) different timepoints pregnancy. antibody
responses antigens detected populations, png women
presenting highest levels overall. p. vivax infection sample collection
time positively associated antibody levels pvlp1 (fold-increase:
1.60 recruitment -first antenatal visit-) pvlp2 (fold-increase: 1.63 at
delivery), p. falciparum co-infection found increase responses
(for pvlp1 recruitment, fold-increase: 2.25). levels igg two vir
proteins delivery associated higher birth weight (27 g increase per 
duplicating antibody levels, p<0.05). peripheral blood mononuclear cells png
uninfected pregnant women significantly higher antigen-specific ifn-γ th1
responses (p=0.006) secreted less pro-inflammatory cytokines tnf il-6
after pvlp2 stimulation p. vivax-infected women (p<0.05). data
demonstrate vir antigens induce natural acquisition antibody t
cell memory responses might important immunity p. vivax during
pregnancy diverse geographical settings.

doi: 10.1371/journal.pntd.0005009 
pmcid: pmc5053494
pmid: 27711158  [indexed medline]

conflict interest statement: hdp co-founder innovex therapeutics sl 
which holds proprietary rights use pvlp1 pvlp2 vaccine candidates
against vivax malaria; thus, potential conflicts interest. no
other conflicts interest.

